Pediatric Systemic Lupus Erythematosus Clinical Presentation
- Author: Marisa S Klein-Gitelman, MD, MPH; Chief Editor: Lawrence K Jung, MD more...
History
The most frequent presenting symptoms of systemic lupus erythematosus (SLE) are prolonged fever and malaise with evidence of multisystem involvement. Children often present with a history of fatigue, joint pain, rash, and fever. However, children may also present with various acute symptoms, including memory loss, psychosis, transverse myelitis, hemoptysis, edema of the lower extremities, headache, and painful mouth sores.
Eleven criteria from the American College of Rheumatology (ACR) are used for the classification of lupus in adults.[5] The same criteria can serve as a guideline in children. Any 4 criteria are sufficient for classificantion and should be sought in the history. (Of note, ANA is almost always present but is not diagnostic.)
The ACR’s diagnostic criteria for SLE include the following:
- Malar rash
- Naso-oral ulcers
- Photosensitive rash
- Discoid rash
- Arthritis
- Pleuritis or pericarditis
- Proteinuria (>500 mg/d) or evidence of nephritis in urinalysis
- Hemolytic anemia, thrombocytopenia, leukopenia, or lymphopenia
- Seizure or psychosis
- Positive ANA finding
- Positive anti–double-stranded DNA, anti-Smith, or antiphospholipid antibody/lupus anticoagulant
Patients should be evaluated for traditional risk factors of atherosclerosis, including smoking history, family history of atherosclerosis, and physical activity. Risks should be stratified and treated.
The diagnosis of SLE is not difficult in a child who presents with many manifestations, such as malar rash, pleuritic chest pain, nephritis, and a positive ANA finding. Some patients present over longer periods and require careful consideration. Occasionally, patients do not fulfill the classification criteria, a definite classification is never made, or the patient may have an overlap syndrome with manifestations of several rheumatic diseases.
Treatment should never be delayed in patients who do not fulfill classification criteria, particularly when patients are seriously ill.
Physical Examination
A detailed physical examination is a critical tool in the diagnosis of systemic lupus erythematosus (SLE). Most of the ACR classification criteria are associated with physical findings.[5] The following is a description of more common clinical manifestations.
Rash occurs in 70-80% of patients. The characteristic rash is a malar, or butterfly, rash, including both cheeks and the nasal bridge sparing the nasolabial fold. The rash varies from an erythematous blush to a thickened epidermis to a scaly rash. (See the image below.)
The classic malar rash, also known as a butterfly rash, with distribution over the cheeks and nasal bridge. Note that the fixed erythema, sometimes with mild induration as seen here, characteristically spares the nasolabial folds. Other common rashes include vasculitic macular eruptions, particularly on the distal extremities and often in the subungual region, with visible microinfarcts from small vessel vasculitis; purpura; livedo reticularis, which is often associated with antiphospholipid antibodies; alopecia, which is usually frontal or hairline; and Raynaud phenomenon, which is characterized by sequential color changes in the fingers and toes.
Less common rashes include subacute psoriasiform or annular skin lesions, often associated with anti-Ro antibodies and bullous lesions, a rare but potentially life-threatening condition as bullae can cover large surfaces and oral mucosa, with loss or skin integrity and compromise of the airway. Other diagnostic skin findings include discoid rash, which is less common in childhood; a photosensitive rash; and mucous membrane changes that range from vasculitic erythema to large, deep ulcers on the palate and nasal mucosa.
Musculoskeletal findings include arthritis, arthralgia, tendonitis, and myositis. Deforming arthritis is unusual and, if present, is usually secondary to a Jaccoudlike arthropathy. This arthritis can lead to ligament damage and severely lax joints.
Avascular necrosis of bone is a frequent complication, occurring in about 25% of children with SLE over time. It is most common in children with SLE who are receiving daily corticosteroids, although it can also occur in children with SLE who are not being treated with corticosteroids and in children receiving corticosteroids for conditions other than SLE.
Patients often present with lymphadenopathy and hepatosplenomegaly. Many have chronic abdominal pain secondary to recurrent vascular insults to the intestinal tract and/or chronic pancreatitis, which may be a result of treatment with corticosteroids or from the SLE itself. Other abdominal findings can include pain secondary to peritoneal serositis or small-vessel vasculitis. The latter can be associated with severe bleeding and necrosis of tissue and is clearly life threatening.
Cardiac involvement includes pericarditis, murmurs associated with valvulitis, carditis, and cardiac failure from myocarditis or infarction. Pulmonary auscultatory findings may be abnormal secondary to pleuritis, infiltrates, or hemorrhage.
Neurologic manifestations can involve the central and the peripheral nervous systems. Clinical findings associated with classification criteria include seizure and psychosis; however, patients may present with stroke, pseudotumor cerebri, cerebral venous thrombosis, aseptic meningitis, chorea, global cognitive deficits, mood disorders, transverse myelitis, and peripheral neuropathy, as well as many less common neurologic findings.
As many as 40% of children may have neurologic disease, and perhaps even more when psychiatric manifestations and cognitive abnormalities are considered. Quantification of cognitive function with formal neuropsychiatric testing may be advisable.
Renal disease is manifested by hypertension, edema of the lower extremities, retinal changes, and clinical manifestations associated with electrolyte abnormalities, nephrosis, or acute renal failure. Renal disease is more frequently observed in children than in adults.
Patients with lupus may present with the clinical findings of endocrine disease, such as hyperthyroidism and Addisonian crisis.
Osler W. On the visceral manifestations of the erythema group of skin diseases. Am J Med Sci. 1904;27:1.
Suzuki M, Ross GF, Wiers K, Nelson S, Bennett M, Passo MH, et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol. Dec 2007;22(12):2047-57. [Medline].
Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. Journal of Experimental Medicine. 2005;201:703-711. [Medline].
Armstrong DL, Reiff A, Myones BL, Quismorio FP Jr, Klein-Gitelman M, McCurdy D. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. May 14 2009;[Medline].
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. Sep 1997;40(9):1725. [Medline].
Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. Dec 15 2005;106(13):4152-8. [Medline].
Ross GS, Zelko F, Klein-Gitelman M, et al. A proposed framework to standardize the neurocognitive assessment of patients with pediatric systemic lupus erythematosus. Arthritis Care Res (Hoboken). Jul 2010;62(7):1029-33. [Medline]. [Full Text].
[Guideline] Brunner HI, Ruth NM, German A, Nelson S, Passo MH, Roebuck-Spencer T. Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. Arthritis Rheum. Oct 15 2007;57(7):1174-82. [Medline].
Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). Sep 2011;63(9):1213-23. [Medline]. [Full Text].
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. Feb 2004;65(2):521-30. [Medline].
Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child. May 2008;93(5):401-6. [Medline].
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. Feb 26 2011;377(9767):721-31. [Medline].

